COPD & ASTHMA -
STATE OF THE ART

Conference Date: 27-28 Jan 2009
Conference Ref: A1-1109
Fee: £1150 + VAT
Venue: The Cavendish Hotel, London

**Special discounted rate of £1,500 if  booked with COPD & ASTHMA – AN INTRODUCTORY COURSE on 26th January 2009 Ref: A1-1009**

INTRODUCTION

Asthma and COPD remain key indications for new drug development. This meeting is intended to bring together experts in this field from industry and academia in order to review novel developments and to discuss their experience.

This meeting will be of great benefit to Medical Directors, Heads of Regulatory and Public Affairs, Senior Executives in Research, Clinical and Technical Departments, Registration, Quality Assurance and marketing departments of the pharmaceutical industry.  It will also be of interest to academics and clinical respiratory specialists.

Attendance will provide an opportunity to meet opinion leaders in the field, and to hear about novel therapies from industry representatives.

Topics to be covered include:

• New concepts of the disease process
• Novel targets for therapeutic intervention
• Outcome measures and biomarkers in clinical trials
• Update of regulatory developments in Europe/USA

Chairmen:   

• Professor Neil Barnes Consultant in Respiratory and General Medicine, The London Chest Hospital, UK
• Dr Noel Snell Consultant Medical Director Argenta Discovery and Honorary Senior Lecturer, NHLI, UK  

Speakers:

• Dr Jan Canvin Novartis
• Dr Trevor Hansel NHLI
• Dr Paul Newbold Astrazeneca
• Professor Michael Polkey NHLI
• Dr Duncan Rogers NHLI
• Professor Rob Stockley University Hospital Birmingham (UHB)
• Dr Anne Thomson Oxford Radcliffe Hospital
• Dr John Warren MHRA